Ajinomoto to produce potential COVID-19 treatment for CytoDyn

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Duncan Andison)
(Image: Getty/Duncan Andison)

Related tags: Ajinomoto Bio-Pharma, CytoDyn, COVID-19, Coronavirus, Leronlimab

Ajinomoto agrees partnership to manufacture leronlimab, which is currently undergoing clinical trials for the treatment of COVID-19.

CytoDyn’s potential treatment, leronlimab, is currently being tested for patients deemed ‘mild-to-moderately ill’ and ‘severely ill’ with COVID-19.

According to the company, the treatment is being administered to patients in the New York City area as part of Phase I, Phase III, and Phase IIb/III clinical trials.

In order to ensure supply, CytoDyn has signed an extended manufacturing agreement with Ajinomoto Bio-Pharma Services for aseptic fill-finish services.

The two partners had already been working together for production of leronlimab for other therapeutics indications.

CytoDyn is exploring the monoclonal antibody for use across a variety of indications, including against HIV as both a monotherapy and as part of a combination treatment, which are both at the Phase III stage.

The company has also taken the treatment to Phase II stage for triple-negative breast cancer and Phase II against a total of 22 solid tumor types.

Leronlimab blocks the CCR5 cellular receptor, which is thought to play a role in tumor metastases and is an indicator of disease status in some cancers. It also plays a role in inflammatory conditions by modulating immune cell trafficking to areas of inflammation, the company suggested.

Yesterday, CytoDyn announced that it had submitted a request to the US Food and Drug Administration for ‘compassionate use’ of patients currently ineligible for its two ongoing clinical trials for COVID-19 patients. Currently, the company has 49 patients enrolled for treatment.

Related news

Show more

Related products

show more

Infographic - road map to commercialization

Infographic - road map to commercialization

MilliporeSigma - Gene Therapy | 19-Oct-2020 | Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Process Development for Viral Vector Manufacturing

Process Development for Viral Vector Manufacturing

MilliporeSigma - Gene Therapy | 15-Oct-2020 | Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...

Related suppliers

Follow us

Products

View more

Webinars